FOR US HEALTHCARE PROFESSIONALS

For the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

Mechanism of action of AURYXIA

Watch this video and see how AURYXIA, an oral iron tablet, works in adult patients.

Chronic kidney disease, CKD, is characterized by a gradual loss of kidney function, causing insufficient synthesis of erythropoietin, a hormone that stimulates red blood cell (RBC) production and a lack of which causes anemia.1 Iron deficiency also causes anemia in CKD patients.1

AURYXIA is a unique formulation of ferric citrate coordination complexes that treats iron deficiency anemia in adults with CKD not receiving dialysis.2-4

Upon swallowing AURYXIA, ferric iron is converted to ferrous iron by the enzyme ferric reductase in the gastrointestinal tract, where the molecules are absorbed in the same highly regulated physiological pathway as dietary iron.2,3,5 In the bloodstream, ferrous iron is oxidized back to ferric iron, which binds to transferrin, an iron transfer protein that transports iron to the bone marrow for incorporation into hemoglobin for RBC production.2,3,5

AURYXIA treats iron deficiency anemia in non-dialysis patients with CKD.2,3

How AURYXIA works to treat iron deficiency anemia

AURYXIA is a unique formulation of ferric citrate coordination complexes that treats iron deficiency anemia in adults with CKD not receiving dialysis.2-4

Ferric iron is converted to ferrous iron by the enzyme ferric reductase in the gastrointestinal tract2,3

The molecules are absorbed in the same highly regulated physiological pathway as dietary iron2,3

In the bloodstream, ferrous iron is oxidized back to ferric iron, which binds to transferrin2,3

Transferrin transports iron to the bone marrow for incorporation into hemoglobin for red blood cell production2,3

CKD=chronic kidney disease.

You may also be interested in: 

PATIENT PROFILE

RESOURCES

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS
The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

INDICATION

AURYXIA® (ferric citrate) is indicated for:

  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information

REFERENCES

  1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-1252.
  2. AURYXIA® [Package Insert]. Cambridge, MA: Akebia Therapeutics, Inc.; 2021.
  3. Ganz T, Bino A, Salusky IB. Mechanism of action and clinical attributes of Auryxia® (Ferric Citrate). Drugs. 2019;79(9):957-968.
  4. Yagil Y, Fadem SZ, Kant KS, et al. Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 2015;6(5):252-263.
  5. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis. 2009;16(2):143-151.